Mc Clarren Financial Advisors, Inc. Amgen Inc Transaction History

Mc Clarren Financial Advisors, Inc.

$795 Million
Q3 2024

A detailed history of Mc Clarren Financial Advisors, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Mc Clarren Financial Advisors, Inc. holds 618 shares of AMGN stock, worth $173,046. This represents 0.03% of its overall portfolio holdings.

Number of Shares

618

Previous 312 98.08%

Holding current value

$173,046

Previous $191,000 4.19%

% of portfolio

0.03%

Previous 0.13%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$309.38 - $337.38 $94,670 - $103,238	306 Added 98.08%	618 $199,000
Q2 2024 Jul 26, 2024	SELL	$262.75 - $319.31 $82,503 - $100,263	-314 Reduced 50.16%	312 $191,000
Q1 2024 Jul 26, 2024	BUY	$268.87 - $324.56 $91,684 - $110,674	341 Added 119.65%	626 $178,000
Q1 2024 May 03, 2024	SELL	$268.87 - $324.56 $90,071 - $108,727	-335 Reduced 54.03%	285 $178,000
Q4 2023 Feb 02, 2024	BUY	$255.7 - $288.46 $1,278 - $1,442	5 Added 0.81%	620 $179,000
Q2 2023 Aug 04, 2023	SELL	$214.27 - $253.37 $3,856 - $4,560	-18 Reduced 2.84%	615 $136,000
Q1 2023 May 05, 2023	BUY	$225.79 - $275.2 $225 - $275	1 Added 0.16%	633 $153,000
Q4 2022 Jan 30, 2023	SELL	$229.03 - $291.01 $7,099 - $9,021	-31 Reduced 4.68%	632 $166,000
Q3 2022 Oct 31, 2022	BUY	$224.46 - $253.15 $148,816 - $167,838	663 New	663 $149,000
Q2 2022 Aug 11, 2022	SELL	$230.71 - $256.74 $154,114 - $171,502	-668 Closed	0 $0
Q1 2022 Apr 29, 2022	BUY	$219.27 - $242.57 $877 - $970	4 Added 0.6%	668 $161,000
Q4 2021 Jan 19, 2022	BUY	$198.88 - $227.6 $132,056 - $151,126	664 New	664 $150,000

Others Institutions Holding AMGN

# of Institutions

3,123

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Clarren Financial Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mc Clarren Financial Advisors, Inc. with notifications on news.

Account

Mc Clarren Financial Advisors, Inc. Amgen Inc Transaction History